Stacie Canan

WORK HISTORY

EDUCATION

SKILLS

ABOUT STACIE CANAN

Stacie is Chief Operating Officer and VP of Drug Discovery at Elgia Therapeutics, Inc. in San Diego, CA. Elgia is pioneering new biological insights to deliver novel medicines for chronic inflammation and fibrosis. Canan previously served as Executive Director of Global Health at Bristol Myers Squibb (formerly Celgene) in San Diego and was responsible for Discovery and Development activities on multiple international global health programs for neglected tropical diseases (NTDs). At Celgene, Stacie also served as Executive Director of Chemistry (20••••12), responsible for chemistry strategy and implementation across the portfolio, including clinical candidate nominations. Stacie has 28 years of experience in the biopharma and pharmaceutical industry, including scientific and leaderships roles at Ligand, Agouron, and Pfizer, with broad expertise that includes project leadership, diverse therapeutic area experience (oncology, inflammation/fibrosis, HIV, HCV, sexual health, ophthalmology and neglected diseases), and success with fragment, structural, phenotypic and property based drug discovery approaches. During her tenure at Agouron, as a member of the discovery team, Stacie co-invented rucaparib (Rubraca®), which is an oral small molecule inhibitor of PARP-1-2-3 for treatment of cancers with BRCA mutations. Roles also include senior management, site responsibilities, business development and leadership of multi-partnered, international research teams. Stacie received her BS in Chemistry from Penn State, a MS in Chemistry from Illinois and PhD in Chemistry from UC Irvine.